Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Robotic and open surgeries for prostate cancer achieve similar quality of life outcomes at 3 months

Robotic and open surgeries for prostate cancer achieve similar quality of life outcomes at 3 months

The first randomised controlled trial to directly compare robotic surgery with open surgery for patients with localised prostate cancer finds that robotic and open surgery achieve similar results in terms of key quality of life indicators at 3 months. [More]
Management of prostate cancer varies by race

Management of prostate cancer varies by race

A study published in The Journal of Urology® indicates that treatment for low-risk prostate cancer, rather than watchful waiting, is most likely to be sought by black men. [More]
Scientists identify new group of molecules that could slow tumour growth in prostate cancer patients

Scientists identify new group of molecules that could slow tumour growth in prostate cancer patients

Prostate cancer patients have been offered hope after scientists at Newcastle University, UK, have identified a new group of molecules that could be targeted to slow tumour growth. [More]
ZMYND8 protein can suppress metastasis-linked genes in prostate cancer

ZMYND8 protein can suppress metastasis-linked genes in prostate cancer

Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center. [More]
Researchers identify genetic variants linked to radiotherapy side-effects in prostate cancer patients

Researchers identify genetic variants linked to radiotherapy side-effects in prostate cancer patients

A new study involving researchers from The University of Manchester looked at the genetic information of more than 1,500 prostate cancer patients and identified two variants linked to increased risk of radiotherapy side-effects. [More]
Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer. [More]
VCU Health radiologist uses MRI technology to detect difficult prostate cancers

VCU Health radiologist uses MRI technology to detect difficult prostate cancers

For three years, Andrew Harder wondered if he had prostate cancer. In 2009, he had routine blood work that revealed an elevated prostate-specific antigen (PSA) level. [More]
New imaging tool may help detect presence of androgen receptor in prostate cancer patients

New imaging tool may help detect presence of androgen receptor in prostate cancer patients

Prostate cancer is one of the most common cancers in men. Tumor growth is critically regulated by the androgen receptor, and treatment strategies to lower androgens, such as testosterone, are a mainstay of clinical treatment. [More]
New study reports significant increase in new metastatic prostate cancer cases

New study reports significant increase in new metastatic prostate cancer cases

The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. [More]
NorthShore launches first clinical trial to examine GRS test for cancer risk assessment

NorthShore launches first clinical trial to examine GRS test for cancer risk assessment

Researchers at NorthShore University HealthSystem have launched the first clinical trial to investigate a genetic risk score (GRS) test to predict the risk of breast, prostate and colorectal cancer in the primary care setting. [More]
OVC research may help improve cancer treatment

OVC research may help improve cancer treatment

Cancer treatment in people could be transformed thanks to a study on treating cancer in animals led by researchers from the Ontario Veterinary College at the University of Guelph. [More]
Smart biodegradable nanoparticle shows promise to target and ablate tumours

Smart biodegradable nanoparticle shows promise to target and ablate tumours

Dr. Gang Zheng and a team of biomedical researchers have discovered a "smart" organic, biodegradable nanoparticle that uses heat and light in a controlled manner to potentially target and ablate tumours with greater precision. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]

Moffitt researchers receive grant to examine prostate cancer metastasis

Moffitt researchers David Basanta, PhD, and Conor Lynch, PhD, have been awarded a U01 grant to investigate prostate cancer metastasis. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Chromatrap reports benefits of ChIP technology in ground breaking research

Chromatrap reports benefits of ChIP technology in ground breaking research

Chromatrap reports on 3 further customer papers published in different prestigious peer reviewed journals, which cite how its proprietary solid state Chromatin Immunoprecipitation (ChIP) technology has enabled ground breaking research. [More]

Swedish researchers shed more light on hereditary prostate cancer

It is a well-known fact that men with a family history of prostate cancer run an increased risk of developing the disease. The risk for brothers of men with prostate cancer is doubled. [More]
Germline genetic testing necessary for men with metastatic prostate cancer

Germline genetic testing necessary for men with metastatic prostate cancer

Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital. [More]
Scientists identify how tumor cells exploit function of mitochondria to support cancer proliferation

Scientists identify how tumor cells exploit function of mitochondria to support cancer proliferation

As the powerhouse of the cells, mitochondria are critical for every organism because of their role in producing energy while also controlling survival, but how they function in cancer is still not completely known. [More]
Study shows miR-19 helps new neurons in the adult brain stay on track

Study shows miR-19 helps new neurons in the adult brain stay on track

A small stretch of ribonucleic acid called microRNA could make the difference between a healthy adult brain and one that's prone to disorders including schizophrenia. [More]
Advertisement